Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio Plc LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 4.92% 0.64 0.64 0.698 0.69 0.628 0.63 3,045,551 12:02:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -11.0 -3.9 - 2

Motif Bio Share Discussion Threads

Showing 4451 to 4471 of 4475 messages
Chat Pages: 179  178  177  176  175  174  173  172  171  170  169  168  Older
DateSubjectAuthorDiscuss
21/10/2019
10:18
They'll burn the 600k by end of month...so it's sqweeky time!
zen12
18/10/2019
13:01
Deal about to be announced
w0lf0fwallstreet
11/10/2019
08:28
Bit boring now from MMs, don't we see this every morning here a sell at ridiculous 15-20% discount!
zen12
10/10/2019
14:39
No money - is that not why they raised 600k last week lol Now don't tell me that won't last long...it may give them enough time to do a deal, my guess they're already talking to many with Hercules.
zen12
10/10/2019
14:06
Traditional Sale - Not as hope in HELL (imo) Shareholders will be very lucky if management are able to negotiate a "free assignment" of ALL research data and IP to another pharma in return for an agreement for a fee of �xxx,000 if new phase 3 results pass FDA and a y% royalty on ongoing sales - subject to which pharma the execution of the terms of this agreement might need to be insured by Lloyds or similar reputable insurance organisation against default.
pugugly
10/10/2019
13:48
ZEN, sales talks take months. They have no money.
shirley83
10/10/2019
13:41
All i know is that my shares are pretty much worthless now so I wont sell for a pittance. My fingers are crossed this comes good but if it doesn't its just beer money i'd lose now!
philoosh
10/10/2019
13:30
HABP/VAP trial costlier & slower to recruit than cABSSSI (skin). ..... &, against what comparator? Still vancomycin? Or vs. linezolid, where there's some (albeit weak) evidence of superiority over vancomycin (unlike in ABSSSI). Directors keen to keep themselves occupied for a few more years at investors' expense.
vulgaris
10/10/2019
13:08
the FDA led the board down a garden path for the last 3 years... and they continue to do so.. if there was a glimmer of hope of iclaprim passing they would have given a box warning.. sell to 0
pjj71
10/10/2019
10:41
..if that was the case FDA wouldn't have been collaborating with MTBF since Feb (8 months), to agree the limited trial and its approval route. It looks like it's been simplified for whoever picks this up. We should now start to see interested parties come forward.
zen12
10/10/2019
10:18
which pharma is going to spend more money after 2 failed phase 3 trials.. the FDA clearly dont want this compound to succeed hence the requirement for yet another trial costing millions and millions to quote the CEO...
pjj71
10/10/2019
07:57
Nope, good news as FDA collaboration discussions over and now they know exactly what's needed. Let the sale talks now begin..
zen12
10/10/2019
07:25
Looks like they are about to throw in the towel - That is reading between the lines of the announcement.
pugugly
10/10/2019
07:22
oh dear... confirmation that the millions spent on the last trials were a complete waste.. who in their right mind would spend more on this wonder drug..
pjj71
10/10/2019
07:10
No money, Need a partner, administration?
letmepass
10/10/2019
07:03
Over and out
best1467
09/10/2019
10:29
BoD need to issue the GM Circular RNS now. It's been a week since the announcement of it.
zen12
08/10/2019
08:36
Haha LMFAO 100 shares traded... Wow.. Someone buying
letmepass
07/10/2019
17:45
Lots of negative share chat here - growth today but lots of trading - interesting to see how the market reacts this month For those interested in pharma stocks Open Orphan ORPH is worth keeping an eye on - CEO Cathal Friel shown serious backing with £2 million of his own money in - predicts 40% growth a year on recent podcast hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year
sunningdale1
07/10/2019
12:36
Ah shut up- what a pile of �&@( you most likely are!! How is that sort of posting helping anybody?
smcl
07/10/2019
10:20
buywell3 - 20 Jun 2019 - 14:08:14 - 4002 of 4239 Motif Bio: Developing novel antibiotics to fight infection - MTFB Sometimes it pays to listen to a negative viewpoint This share was a case in question Links were posted to support the argument many times The post and subsequent ones were either ridiculed in the main by what I suppose were holders/rampers of the shares. This was my first heads up buywell3 - 18 Feb 2019 - 19:22:09 - 3279 of 4003 Motif Bio: Developing novel antibiotics to fight infection - MTFB I would imagine the FDA have a problem with the following 1. How does any person taking , or any doctor that may prescribe, this drug( if approved), know the exact state of the liver function in question, that will have to process the drug and thus because of the AUC problems identified by the FDA ,perhaps suffer damage ? 2. Assuming some sort of test could be made to assess the exact state of liver function of the patient to take the drug then there would most likely have to be at least 3 different dose options to choose from. 3. Risk of wrong dose options being prescribed then exist The FDA are going to play safe whatever , they have to withdraw enough approved drugs as it is. Around 50% of the FDA approved drugs that have to be withdrawn as a Class 1 recall(most serious) are due to guess what ? liver damage From original European submission back in 2009. A mild impaired hepatic function has a slight effect on the exposure of iclaprim (30% increase). AUC more than doubled in subjects with a moderate hepatic impairment. In case the dose was halved, AUC was only a little higher than the AUC observed in normal subjects. The SPC recommends no dose adjustment for subjects with a mild hepatic impairment, and a dose reduction of 50% for patients with a moderate hepatic impairment, which is agreed based upon the pharmacokinetic results.
buywell3
Chat Pages: 179  178  177  176  175  174  173  172  171  170  169  168  Older
Your Recent History
LSE
MTFB
Motif Bio
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191023 12:54:43